Zura Bio Limited announced the Board of Directors appointed Arnout Ploos van Amstel as Non-Executive Independent Director by way of co-optation. Mr. Ploos van Amstel replaces Dr. Garry Neil who will continue to support Zura Bio as an advisor on R&D matters. With a career spanning over three decades in the global biotech and pharmaceutical sector, Mr. Ploos van Amstel has built a successful track record in a wide variety of leadership positions.

He consistently excelled in devising and implementing comprehensive strategies across Development, Medical, and Commercial-Access domains. He currently works as a strategic consultant through his company Apaxcel Life Sciences GmbH, and he is a founder of MoonLake Immunotherapeutics AG, a biotech company dedicated to next-level therapies in inflammatory diseases. During his tenure as the leader of Novartis' Global Business Unit Immunology/Dermatology, he achieved remarkable portfolio growth, notably with the success of COSENTYX® (secukinumab), XOLAIR® (omalizumab) for chronic spontaneous urticaria (CSU), and with the consistent growth of "orphan blockbuster" ILARIS® (canakinumab).

Mr. Ploos van Amstel's experience includes leadership roles at Wyeth Pharmaceuticals and Novartis with executive positions in the United States, Canada, Greece, the Netherlands and Switzerland.